This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
UnitedHealth 2025 Outlook Clouded by Heartbreaking Loss of Key Leader
by Zacks Equity Research
UNH expects 2025 operating cash flows to be within $32-$33 billion.
Recalculation Ahead: Implications of UnitedHealth's Win Against CMS
by Kaibalya Pravo Dey
UNH's success marks the third recent defeat for CMS in star ratings lawsuits, raising hopes for Humana and Centene as they challenge their own ratings.
UnitedHealth Stock Up 12.7% YTD: Is its Premium Valuation Justified?
by Kaibalya Pravo Dey
UNH and the broader health insurance industry will likely focus on cost-cutting initiatives and lobbying for better government reimbursement rates over time.
Elevance Health Declines 20% in 3 Months: Time to Sell the Stock?
by Debasmita Chatterjee
ELV encounters headwinds such as higher benefit costs, an increased debt level and member attrition in the Medicaid business, which raise concerns among investors.
Beyond UnitedHealth's Q3 Earnings: Time to Reevaluate & Sell Stock?
by Kaibalya Pravo Dey
Looking ahead to 2025, UNH projects adjusted earnings to reach around $30 per share at the top end, which falls short of the Zacks Consensus Estimate.
Zacks Industry Outlook Highlights Elevance Health, Doximity and HealthEquity
by Zacks Equity Research
Elevance Health, Doximity and HealthEquity are part of the Zacks Industry Outlook article.
Elevance Health's Q3 Earnings Miss Due to Medicaid Redeterminations
by Zacks Equity Research
ELV's third-quarter earnings are hurt by declining membership in Medicaid and Medicare, partially offset by improved product revenues.
3 Medical Services Stocks to Buy to Navigate Industry Challenges
by Urmimala Biswas
The Zacks Medical - Services industry is growing on nursing care market growth and digital healthcare adoption. ELV, DOCS and HQY are set to gain the most. Healthcare staffing shortages are leading to an increase in labor wages.
Compared to Estimates, Elevance Health (ELV) Q3 Earnings: A Look at Key Metrics
by Zacks Equity Research
Although the revenue and EPS for Elevance Health (ELV) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Elevance Health (ELV) Q3 Earnings Lag Estimates
by Zacks Equity Research
Elevance Health (ELV) delivered earnings and revenue surprises of -13.71% and 3.37%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Will Elevance Health (ELV) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Elevance Health (ELV) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Elevance's Pre-Q3 Earnings Analysis: Smart Buy Now or Caution Ahead?
by Zacks Equity Research
ELV's third-quarter results are likely to reflect growing operating income from the Carelon business.
Gear Up for Elevance Health (ELV) Q3 Earnings: Wall Street Estimates for Key Metrics
by Zacks Equity Research
Besides Wall Street's top -and-bottom-line estimates for Elevance Health (ELV), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended September 2024.
Elevance Health (ELV) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Elevance Health (ELV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why You Should Add Elevance Health Stock to Your Portfolio
by Zacks Equity Research
ELV benefits from an increase in employer group fee-based memberships, partially offsetting the impact of Medicaid memberships.
Should You Invest in the iShares U.S. Healthcare Providers ETF (IHF)?
by Zacks Equity Research
Sector ETF report for IHF
ELV vs. GDRX: Which Stock Is the Better Value Option?
by Zacks Equity Research
ELV vs. GDRX: Which Stock Is the Better Value Option?
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Elevance Health Stock Has More to Offer: Should You Hold on Tight?
by Zacks Equity Research
In the commercial category, an increase in individual as well as employer group fee-based memberships will continue supporting ELV's medical membership numbers.
Why Is Cencora (COR) Down 2.8% Since Last Earnings Report?
by Zacks Equity Research
Cencora (COR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Icon PLC (ICLR) Up 2.3% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Icon PLC (ICLR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Is Elevance Health (ELV) Up 7.3% Since Last Earnings Report?
by Zacks Equity Research
Elevance Health (ELV) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Pediatrix (MD) Q2 Earnings Top on Stable Volumes, Shares Up 7.4%
by Zacks Equity Research
Pediatrix's (MD) second-quarter earnings benefit from stable patient volumes. Rising expenses act as a partial offset.